October 2, 2022

IOL Chemicals launches commercial production of paracetamol


IOL Chemicals & Pharmaceuticals said it began commercial production of “Paracetamol” with an installed capacity of 1,800 MTPA as well as the upstream integration of Para Amino Phenol (PAP) effective April 22, 2022.

Paracetamol, also known as acetaminophen, is an active pharmaceutical ingredient (API) used to treat fever and mild pain, while PAP is used as an intermediate to make paracetamol.



The company manufactures paracetamol in its existing unit number 4, which has been converted into a multi-product facility, at a cost of around Rs 1 crore while PAP is manufactured in part of unit number 9. The company will continue to use unit 4 and unit 9 for the manufacture of other products according to market conditions.

Further, considering the current market scenario, the company is in the process of increasing the installed paracetamol manufacturing capacity from 1,800 MTPA to 3,600 MTPA with an investment of around Rs 25 crore, which is expected to be completed during of the third quarter of fiscal year 2023. . All investments are covered only by internal accruals, the company said.

IOL Chemicals & Pharmaceuticals is a leading pharmaceutical (API) company and a major player in the field of specialty chemicals. The Company’s product portfolio includes APIs such as ibuprofen, metformin, fenofibrate, clopidogrel, lamotrigine, pantoprazole and specialty chemicals such as ethyl acetate, isobutylbenzene, monochloroacetic acid and acetyl chloride.

The company’s net profit decreased by 65.10% to Rs 40.07 crore on an 8.21% increase in sales to Rs 555.14 crore in Q3 FY22 compared to Q3 FY21.

The certificate lost 0.22% to end at Rs 455.20 on BSE yesterday.

Powered by Capital Market – Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor